Mark McAllister is a research fellow in the Drug Product Design group, Pharmaceutical Sciences, Pfizer, located in Sandwich, UK. He graduated in Pharmacy from Queens University Belfast in 1990 and completed a pharmaceutics PhD at Aston University under the supervision of Prof. Oya Alpar. Since joining Pfizer in 2008 to lead the Research Formulation drug delivery group, he has continued his research interests in biopharmaceutics and provided formulation support for programmes in early discovery through to proof-of-concept stage. More recently, he has moved into the Drug Product Design group and has responsibility for mid-to-late stage development projects.
Dr. McAllister was recently made a Fellow of the Royal Pharmaceutical Society and he is the current chairman of the UK Academy of Pharmaceutical Scientists (APS). He also leads the APS Biopharmaceutics focus group. He is the deputy scientific coordinator for the Innovative Medicines Initiative ‘OrBiTo’ project, a pre-competitive consortium involving 27 partners assembled from academia, industry and specialist technology companies, which is seeking to develop the next generation of in vitro and in silico tools to predict oral absorption.